Stock LUPIN LUPIN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lupin Limited NSE India S.E.

Equities

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:48 2024-04-26 am EDT 		5-day change 1st Jan Change
1,616 INR +1.35% Intraday chart for Lupin Limited +4.42% +22.15%
Apr. 24 Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility MT
Apr. 22 INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains RE

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 334,438 267,133 463,185 339,061 294,760 736,424 - -
Enterprise Value (EV) 1 379,293 285,450 476,416 366,521 324,269 761,323 745,942 726,773
P/E ratio 55.3 x -99.1 x 38.2 x -22.2 x 68.8 x 37.4 x 32 x 26.2 x
Yield 0.68% 1.02% 0.64% 0.54% 0.62% 0.44% 0.53% 0.63%
Capitalization / Revenue 2 x 1.74 x 3.05 x 2.07 x 1.77 x 3.71 x 3.39 x 3.07 x
EV / Revenue 2.27 x 1.86 x 3.14 x 2.23 x 1.95 x 3.83 x 3.43 x 3.03 x
EV / EBITDA 13.2 x 12.1 x 18.6 x 16.9 x 18.8 x 20.9 x 17.7 x 14.9 x
EV / FCF 55.7 x 35.9 x 41.6 x -68.2 x 81.6 x 58.3 x 35.4 x 28.9 x
FCF Yield 1.79% 2.79% 2.4% -1.47% 1.23% 1.72% 2.82% 3.45%
Price to Book 2.44 x 2.13 x 3.36 x 2.79 x 2.36 x 5.21 x 4.58 x 4.01 x
Nbr of stocks (in thousands) 452,494 452,998 453,680 454,475 454,981 455,750 - -
Reference price 2 739.1 589.7 1,021 746.0 647.8 1,616 1,616 1,616
Announcement Date 5/15/19 5/28/20 5/12/21 5/18/22 5/9/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 167,182 153,748 151,630 164,055 166,417 198,661 217,377 239,858
EBITDA 1 28,822 23,548 25,669 21,656 17,206 36,412 42,063 48,925
EBIT 1 25,252 13,846 16,795 5,069 8,399 26,419 31,343 37,424
Operating Margin 15.1% 9.01% 11.08% 3.09% 5.05% 13.3% 14.42% 15.6%
Earnings before Tax (EBT) 1 15,172 7,572 16,764 -13,726 7,165 25,289 30,167 36,937
Net income 1 6,066 -2,694 12,165 -15,280 4,301 19,847 23,228 28,287
Net margin 3.63% -1.75% 8.02% -9.31% 2.58% 9.99% 10.69% 11.79%
EPS 2 13.36 -5.950 26.72 -33.65 9.410 43.26 50.55 61.56
Free Cash Flow 1 6,806 7,957 11,441 -5,378 3,974 13,058 21,057 25,106
FCF margin 4.07% 5.18% 7.55% -3.28% 2.39% 6.57% 9.69% 10.47%
FCF Conversion (EBITDA) 23.61% 33.79% 44.57% - 23.09% 35.86% 50.06% 51.32%
FCF Conversion (Net income) 112.21% - 94.05% - 92.39% 65.8% 90.65% 88.76%
Dividend per Share 2 5.000 6.000 6.500 4.000 4.000 7.151 8.549 10.15
Announcement Date 5/15/19 5/28/20 5/12/21 5/18/22 5/9/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 40,174 37,831 42,702 40,913 41,609 38,830 37,438 41,455 43,222 44,301 48,141 48,189 48,810 50,871 52,043
EBITDA 1 7,787 7,076 9,647 5,557 3,698 2,666 1,639 4,342 5,160 6,040 8,565 8,076 8,705 9,950 -
EBIT 1 5,344 4,918 7,560 -3,636 1,664 -605.4 -288.9 2,307 2,956 3,401 6,218 5,627 5,621 7,472 7,286
Operating Margin 13.3% 13% 17.7% -8.89% 4% -1.56% -0.77% 5.57% 6.84% 7.68% 12.92% 11.68% 11.52% 14.69% 14%
Earnings before Tax (EBT) 1 5,248 5,184 7,505 -22,048 1,671 -851.6 22.7 2,096 2,461 2,585 5,588 5,462 5,626 6,435 -
Net income 1 4,382 4,604 5,425 -20,980 5,455 -5,180 -890.8 1,297 1,535 2,360 4,523 3,969 4,436 5,229 -
Net margin 10.91% 12.17% 12.7% -51.28% 13.11% -13.34% -2.38% 3.13% 3.55% 5.33% 9.39% 8.24% 9.09% 10.28% -
EPS 2 9.700 10.11 11.91 -46.22 11.98 -11.40 -1.960 2.850 3.360 5.160 9.900 8.267 9.445 10.42 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/28/21 5/12/21 8/10/21 10/27/21 2/3/22 5/18/22 8/3/22 11/9/22 2/9/23 5/9/23 8/3/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 44,855 18,317 13,231 27,460 29,509 24,899 9,518 -
Net Cash position 1 - - - - - - - 9,651
Leverage (Debt/EBITDA) 1.556 x 0.7779 x 0.5155 x 1.268 x 1.715 x 0.6838 x 0.2263 x -
Free Cash Flow 1 6,806 7,957 11,441 -5,378 3,974 13,058 21,057 25,106
ROE (net income / shareholders' equity) 4.44% 2.68% 9.24% -11.8% 3.49% 14.3% 15.2% 16.1%
ROA (Net income/ Total Assets) 2.24% 1.33% 5.01% -6.73% 1.92% 8.38% 9.42% 10.9%
Assets 1 271,278 -202,214 242,971 227,157 223,883 236,905 246,612 259,211
Book Value Per Share 2 303.0 277.0 304.0 267.0 274.0 310.0 353.0 403.0
Cash Flow per Share 2 36.70 32.40 40.00 8.080 41.50 51.20 63.20 72.30
Capex 1 9,854 6,731 6,776 9,051 14,996 8,195 8,224 8,351
Capex / Sales 5.89% 4.38% 4.47% 5.52% 9.01% 4.12% 3.78% 3.48%
Announcement Date 5/15/19 5/28/20 5/12/21 5/18/22 5/9/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lupin Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,616 INR
Average target price
1,516 INR
Spread / Average Target
-6.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LUPIN Stock
  4. LUPIN Stock
  5. Financials Lupin Limited